Two Chinese biotechs have axed plans to list in New York and instead aim to raise up to $800 million in Hong Kong IPOs, seeking to cash in on new rules to woo early-stage drug developers, sources said.

Continue reading this story with a subscription to DealStreetAsia.
Already a subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com.